Home Insiders Updates Is it a good time to sell Landos Biopharma Inc. [LABP] shares after an insider sold 300,000 shares?

Is it a good time to sell Landos Biopharma Inc. [LABP] shares after an insider sold 300,000 shares?

Is it a good time to sell Landos Biopharma Inc. [LABP] shares after an insider sold 300,000 shares?

Landos Biopharma Inc.’s recent filing unveils that its 10% Owner RTW INVESTMENTS, LP unloaded Company’s shares for reported $0.21 million on Sep 23. In the deal valued at $0.69 per share,300,000 shares were sold. As a result of this transaction, RTW INVESTMENTS, LP now holds 3,975,722 shares worth roughly $ 1.03 million.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Then, Bassaganya-Riera Josep sold 33,194 shares, generating $157,804 in total proceeds. Upon selling the shares at $4.75, the 10% Owner now owns 4,994,208 shares.

Before that, Bassaganya-Riera Josep sold 36,000 shares. Landos Biopharma Inc. shares valued at $174,096 were divested by the 10% Owner at a price of $4.84 per share. As a result of the transaction, Bassaganya-Riera Josep now holds 5,027,402 shares, worth roughly $1.31 million.

Jefferies downgraded its Landos Biopharma Inc. [LABP] rating to a Hold from a a Buy in a research note published on Monday, April 12, 2022; the price target was decreased to $1.40 from $30. PT values the company’s stock at a premium of 81.43 to its Monday closing price. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “a Mkt perform”. Craig Hallum began covering LABP with “Buy” recommendation on October 20, 2021. H.C. Wainwright started covering the stock on October 19, 2021. It rated LABP as “a Buy”.

Price Performance Review of LABP

On Monday, Landos Biopharma Inc. [NASDAQ:LABP] saw its stock fall -18.65% to $0.26. On the same session, the stock had its day’s lowest price of $0.25, but rose to a high of $0.318. Over the last five days, the stock has lost -23.99%. Landos Biopharma Inc. shares have fallen nearly -94.65% since the year began. Nevertheless, the stocks have fallen -98.22% over the past one year. While a 52-week high of $15.00 was reached on 01/04/22, a 52-week low of $0.30 was recorded on 11/07/22. SMA at 50 days reached $0.6608, while 200 days put it at $1.1350. A total of 0.58 million shares were traded, compared to the trading of 4.52 million shares in the previous session.

Levels Of Support And Resistance For LABP Stock

The 24-hour chart illustrates a support level at 0.2320, which if violated will result in even more drops to 0.2070. On the upside, there is a resistance level at 0.3000. A further resistance level may holdings at 0.3430. The Relative Strength Index (RSI) on the 14-day chart is 22.86, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0581, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.45%. Stochastics %K at 6.73% indicates the stock is a buying.

How much short interest is there in Landos Biopharma Inc.?

A steep rise in short interest was recorded in Landos Biopharma Inc. stocks on Jul 14, 2022, dropping by -0.17 million shares to a total of 0.13 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 0.31 million shares. There was a decline of -129.28%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.18% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.17.

Landos Biopharma Inc. [LABP] – Who Are The Largest Shareholders?

In filings from Perceptive Advisors LLC, it is revealed that the company now owns 14,869,915 shares, or roughly 36.94% of the outstanding LABP shares. Additionally, Renaissance Technologies LLC increased 14.17% of its stake after which the total value it holdings stand at $252,676, while BlackRock Fund Advisors reduced -37.59% of its stake to hold $0.19 million in the firm. Over the last quarter, Bridgeway Capital Management LLC sold -10,000 shares of Landos Biopharma Inc., while Macquarie Investment Management B sold 0 shares. At present, Botty Investors LLC is holding 127,262 shares valued at $82720.0. The Vanguard Group, Inc. owned 125,349 shares of the company at the time of its most recent 13F filing, worth $81477.0.

According to FactSet, Landos Biopharma Inc.’s share price will average $1.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 493.75 percent from its previous closing price of $0.32. Analysts expect Landos Biopharma Inc. stock to reach the higher price of $3.00, while the lowest price estimate is $0.80. However, 2 analysts have rated LABP stock as a Hold in their predictions for 2022. The most recent change occurred on March 01, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.


Please enter your comment!
Please enter your name here